State of the art: Systemic rosacea management

Schaller, M.; Schöfer, H.; Homey, B.; Gieler, U.; Lehmann, P.; Luger, T. A.; Ruzicka, T. und Steinhoff, M. (2016): State of the art: Systemic rosacea management. In: Journal Der Deutschen Dermatologischen Gesellschaft, Bd. 14, Nr. S 16: S. 29-37

Abstract

Based on numerous trials, oral tetracyclines and most commonly their second-generation derivative doxycycline have become the main pillar in systemic rosacea treatment. However, the only preparation that has been approved so far in this setting is 40 mg doxycycline in an anti-inflammatory dosage and with a modified release formulation. With the introduction of this once-daily, non-antibiotic dosing of doxycycline, oral therapy is more commonly prescribed as first-line treatment in moderate to severe papulopustular rosacea. In addition, topical and oral strategies are often used in combination due to the more substantial improvements compared to monotherapy. Although several other non-approved oral agents like macrolides, isotretinoin, and carvedilol have been evaluated for systemic treatment and showed promising results, yet the experience with these drugs in rosacea is limited, and thus they should be reserved for special situations.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1610-0379
• Sprache: Englisch